News

11. Clinical Reference Laboratory Creates Unique Position In South America 4/4/2012
    A global leader in the provision of central laboratory services for the clinical trials industry, Clinical Reference Laboratory (CRL), has recently announced the full integration of its Argentina-based partner Laboratorio Hidalgo to its worldwide network of laboratories providing a much desired South American presence.
12. Clinical Reference Laboratory Strengthens Its Position In Asia 3/12/2012
    Clinical Reference Laboratory (CRL), a global leader in the provision of central laboratory services for the clinical trials industry, has recently announced the full integration of its long-standing laboratory partner Phoenix Pharma Central Services in Singapore.
13. Celerion And Ricerca Biosciences Announce 'The Biosimilars Alliance' To Offer Clients A More Effective Development Path For Biosimilars 3/1/2012

    Celerion, the premier provider of innovative early stage drug development solutions, and Ricerca Biosciences, a drug safety assessment expert in harnessing external preclinical innovation, announce the formation of “The Biosimilars Alliance”.

14. Absorption Systems' Innovation Rewarded With New U.S. Patent For CellPort Technologies 2/22/2012
    Absorption Systems, a world leader in drug transporters, announces that a new U.S. patent issued on January 31^st, protecting intellectual property around its P-glycoprotein (P-gp) knockdown cell line within the company’s CellPort Technologies brand.
15. Premier Research Expands Salt Lake City And Phoenix Testing Facilities Adding 50% Capacity 2/22/2012
    Premier Research Group Limited announces the opening of new state-of-the-art clinical research facilities located in Phoenix and Salt Lake City, increasing their testing facilities capacity by 50%.
16. Roche's xCELLigence Cardio Instrument Used To Detect Beating Rhythm And Proarrhythmic Effects Of Compounds In Stem Cell-Derived Cardiomyocytes 2/10/2012
    In an effort to improve preclinical cardiotoxicity assays, reduce drug testing attrition rates, and ensure drug safety, collaborating scientists at the University Medical Center Utrecht in the Netherlands, and Bioscience Department of AstraZeneca R&D, Mölndal, Sweden, have tested Roche’s xCELLigence Cardio Instrument.
17. Oracle Health Sciences Institute, In Partnership With Oracle Labs, Announces First Round Of Research Projects 2/3/2012
    Oracle Health Sciences Institute, in partnership with Oracle Labs, recently announced its first group of research projects, which includes initiatives with Brigham and Women’s Hospital and Harvard Medical School; the Coalition Against Major Diseases (CAMD) at the Critical Path Institute; the Human-Computer Interaction Lab (HCIL) at the University of Maryland.
18. Premier Research Names Dr. Colin Hayward As European Medical Director 1/18/2012
    Premier Research Group announces the appointment of Dr. Colin Hayward to the position of European Medical Director. In this position, Dr. Hayward will be responsible for leading and developing the company’s European medical affairs and pharmacovigilance operations, critical components of the company’s global clinical development services offered to the biopharmaceutical industry.
19. New Phase III Data Shows Novartis JAK Inhibitor INC424 Significantly Reduced Disease Burden In Patients With Myelofibrosis 12/14/2011
    Novartis recently announced additional results from two pivotal Phase III trials evaluating Janus kinase (JAK) inhibitor INC424 (ruxolitinib) in myelofibrosis.
20. New Data Confirms Novartis Drug Afinitor Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 12/9/2011
    The study findings, which represent an additional five months of follow-up, were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), abstract #S3-7.